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of clotting factor deficiency, mainly FXII), and 
women with recurrent spontaneous pregnancy 
loss.3 The latest clinical guidelines of the Nation‑
al Institute for Health and Care Excellence also 
recommend testing for antiphospholipid antibod‑
ies: in patients who have had unprovoked deep 
vein thrombosis (DVT) or pulmonary embolism 
(PE; if withdrawal of anticoagulation treatment 
is planned); and in patients who have had unpro‑
voked DVT or PE and have a first ‑degree relative 
with previous DVT or PE.4
In addition, we would not lightly discard 
the option to treat positive (especially so called 
“triple positive”) patients indefinitely in the light 
of recent data showing that, in patients diag‑
nosed with antiphospholipid syndrome during 
the 10 ‑year period, 36.5% of the fatal cases were 
related to severe thrombosis.5
We hope this additional information will help 
readers of the Polish Archives of Internal Medicine 
decide whether thrombophilia testing may be of 
value for primary and secondary VTE prophylax‑
is in their patients.
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To the Editor We read the review article by Paul 
A. Kyrle with great interest.1 We fully agree with 
the author that systematic indiscriminate lab‑
oratory thrombophilia screening in all patients
with the first unprovoked venous thromboem‑
bolic episode (VTE) is unwarranted and should
be discouraged. However, there is still1 one im‑
portant and unanswered question: who should be
screened for thrombophilia? We would all proba‑
bly agree that owing to age dependency of VTE,
elder patients should not be screened. However,
those aged from 45 to 50 years (or even young‑
er) with unprovoked episodes certainly require
our attention. At this point, some differences
regarding inherited and acquired thrombophil‑
ia may be of issue.
The utility of laboratory investigation for in‑
herited thrombophilia in patients with VTE and 
their asymptomatic relatives has been largely de‑
bated, leading to the production of several guide‑
lines by scientific societies and various working 
groups. As the risk largely depends on the fam‑
ily history of VTE, the identification of asymp‑
tomatic carrier among relatives of the probands 
with VTE and thrombophilia could reduce cases 
of provoked VTE by offering them primary anti‑
thrombotic prophylaxis during risk situations. In 
most guidelines, this is considered justified only 
for relatives of probands with a deficiency of nat‑
ural anticoagulants or multiple abnormalities. 
Counselling asymptomatic female relatives of in‑
dividuals with VTE and/or thrombophilia before 
planned conception or treatment with hormon‑
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pending on the risk driven by the type of throm‑
bophilia and the family history of VTE.2
Acquired thrombophilia mainly involves test‑
ing for antiphospholipid antibodies necessary to 
establish the diagnosis of antiphospholipid syn‑
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tibodies is low or available data are of poor qual‑
ity, we still believe the testing may be warrant‑
ed. The tested group should include: younger pa‑
tients (<50 years), patients with a systemic auto‑
immune disease and any VTE episode in history, 
patients with accidentally found prolonged acti‑
vated partial thromboplastin time (after exclusion 
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